Get started

Moving Averages

BNB at Reversal Incoming or Start of a Deep Correction?BNB has pulled back sharply from its parabolic run above $1,300, and price is now sitting exactly on the bottom boundary of the rising channel that has guided the trend since late 2023. This area is extremely important because: • It is the channel support • It aligns with a previous consolidation zone • It’s very close to the 50-day SMA retest zone (which BNB often respects) If this support holds, BNB could stage a recovery rally. But if it breaks down, the chart opens the door to a much deeper correction. Bullish Scenario (If channel support holds) Entry Zone: $780–$820 (BNB is currently inside this zone) Target 1: $987 – This is the next major resistance and midpoint of the previous structure. Target 2: $1,070–$1,100 – Retest of the recent breakdown area and 50-day SMA region. Target 3 (extended): $1,250+ – Only if momentum continues and BTC supports the market. Bearish Scenario (If price loses the channel) A breakdown from the channel plus a daily close below $790 would confirm weakness. Downside Targets: • $700 — First Fibonacci + structural support • $620 — Major support zone from 2024 • $500–$520 — Full channel breakdown target Stop-Loss Suggestion • Stop-loss (swing trade): $760 – A daily close below this level means the channel is broken. • Tighter stop-loss (short-term): $780 Summary BNB is sitting on a critical support level. Hold → strong bounce potential. Break → deep correction likely.
CRYPTO:BNBUSDLong
by isahebdadi
Pfizer (PFE) – Hedged Covered Call Income CampaignAfter Pfizer’s return to price levels closer to its pre-COVID range, I personally believe the stock is undervalued relative to its current earnings profile and long-term potential. This view is also influenced by Pfizer’s recent acquisition of Metsera, which brings a pipeline of obesity and cardiometabolic candidates — including GLP-1 receptor agonists, an amylin analog, and other metabolic therapies. Whether this pipeline ultimately succeeds is uncertain, but in my opinion, it meaningfully strengthens Pfizer’s long-term outlook. This campaign is structured as a hedged, conservative covered-call income strategy, combining downside protection with steady premium generation. Current Position 1. Long Shares: 700 shares @ $24.94 2. Protective Long Puts: 7 puts @ $19 strike (exp. 1/16/26), Cost: $35 total Because PFE’s implied volatility is relatively low, these long-dated puts provide very inexpensive downside protection, defining maximum risk and allowing me to run covered calls with confidence. This is my preferred way to reduce tail risk on slower-moving stocks. Covered Calls (Income) I am selling near-term calls at the $25 strike and rolling as needed. Call Activity So Far: A. Initial Sell • 7 contracts @ $0.11 → $77 total • Expiration: 11/07/2025 B. Roll #1 • 7 contracts @ $0.15 → $105 total • Expiration: 11/11/2025 C. Roll #2 • 7 contracts @ $0.15 → $105 total • Expiration: 11/17/2025 Dividend Component: Pfizer’s dividend provides a third income source that complements the weekly call premiums. With 700 shares, my next scheduled dividend payment is $310.89 on December 1st. this is nearly a 7% yield. Dividends enhance this strategy by: 1. Reducing effective cost basis over time 2. Providing a reliable quarterly income 3. Making slower-moving stocks like PFE well-suited for hedged income trading 4. Smoothing returns even during flat price periods This is one reason I favor PFE for long-term defensive income strategies. These rolls follow my usual “roll out only” approach — extending time value without paying unnecessary extrinsic premium. This keeps weekly income stable while managing assignment risk.
NYSE:PFELong
by Wallstreet-Warriors
1
Zoetis $ZTS – Weekly Capitulation Scout SignalZoetis has triggered a fresh Capitulation Scout signal on the weekly timeframe (Fig. 1), pointing to a potential early bottoming phase Downside momentum is showing signs of exhaustion, which often precedes medium- to long-term reversals in this setup The next weeks may offer attractive opportunities to begin building long-term positions Previous signals of this type worked well: LVMH EURONEXT:MC (Fig. 2) and Samsung $005930 (Fig. 3) both marked strong accumulation zones before multi-month recoveries: I’ll be monitoring for confirmation and potential scale-in levels Not financial advice. For educational purposes only
NYSE:ZTSLong
by OfficerDonut
Intel Rallied and Now It’s Pulled BackIntel had a dramatic rally in recent months, and now it has pulled back. The first pattern on today’s chart is the gap on September 18 after the chipmaker received an investment from Nvidia. INTC pulled back to hold a 50 percent retracement of that move, which may confirm its upward direction remains intact. Second, prices are near the rising 50-day simple moving average. That may be consistent with a bullish intermediate-term trend. Next, stochastics have dipped to an oversold condition. Finally, INTC is an active underlier in the options market. That may help traders take positions with calls and puts. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com . Visit www.TradeStation.com for full details on the costs and fees associated with options. Margin trading involves risks, and it is important that you fully understand those risks before trading on margin. The Margin Disclosure Statement outlines many of those risks, including that you can lose more funds than you deposit in your margin account; your brokerage firm can force the sale of securities in your account; your brokerage firm can sell your securities without contacting you; and you are not entitled to an extension of time on a margin call. Review the Margin Disclosure Statement at www.TradeStation.com . TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NASDAQ:INTC
by TradeStation
How To Catch The Pullback - Part 1Forex ticker: OANDA:EURJPY OANDA:USDJPY OANDA:AUDJPY OANDA:CADJPY Step 1 — Interpret MACD Colors Only (Bullish Table) Given: • 1H: Light Green 🟢 • 4H: Light Green 🟢 • Daily: Dark Green 🟢 + Rising Three Soldiers From the Bullish MACD Table: Daily 4H 1H Interpretation Probability 🟢 Dark Green 🟢 Light Green 🟢 Light Green Daily regaining strength, intraday momentum accelerating 🟠 75-85% MACD-only base probability: 75-85% (High) Step 2 — Add Candlestick Pattern Given Pattern: • Daily: Rising Three Soldiers + Dark Green MACD From Bullish Candlestick Table: Daily - Rising Three Soldiers + Dark Green: Three White Soldiers + 🟢 Daily + 🟢 4H + 🟢 1H → 95% base → 99% final Since your 4H and 1H are Light Green (not full Dark Green), the probability adjusts slightly but remains very high due to the strength of the Rising Three Soldiers pattern. Step 3 — Combine for Final Probability This is a very strong bullish setup: Strengths: • Strong MACD alignment: Daily Dark Green (maximum momentum), 4H & 1H Light Green (bullish momentum building) • Powerful bullish pattern: Rising Three Soldiers on Daily (strongest pattern in your system) • Good confluence across all timeframes • All timeframes aligned bullish Final Probability: 🔥 90-95% (Very High) Trade Insight: This represents a high-probability bullish continuation setup because: • Daily shows maximum bullish momentum with the strongest pattern (Rising Three Soldiers) • 4H and 1H confirm with bullish momentum (Light Green) • Rising Three Soldiers indicates sustained buying pressure across multiple sessions • Perfect setup for continued upward movement Action: Excellent long entry - strong setup: • Enter on any pullback toward Daily Rising Three Soldiers support • Add positions on break above recent highs • Place stops below the Daily Rising Three Soldiers pattern low • Expect strong upward continuation This is a high-confidence bullish trade with the strongest pattern (Rising Three Soldiers) aligned with solid momentum across all timeframes. The Daily pattern provides exceptional bullish conviction that overrides the slightly weaker momentum on lower timeframes. Rocket Boost this content to learn more Warning! : Trading is risky please learn risk management and profit taking strategies also use a simulation trading account before you trade with real money
Long
by lubosi
USDZAR SWING LONGStrong MACD Divergence is building. I plan to dollar-cost-average my buys as the price declines. Long term target is above 20 🚀 Will start reducing position and taking semi profits @ 18 @18.3 and @ 19, after that I will let my remaining buy orders run. Keep an eye on fundamentals and market behavior 👀 This trade idea will take a long time ⌚ Patience is key 🧘‍♀️ DISCLAIMER❗ My strategy is considered risky; I will continue to average into my position no matter how low the price goes. Follow your own plan and emphasis on Money Management 💸
Long
by David-J
2
$META: at the 100 WMANASDAQ:META : I believe April 2025 low started a new 5-wave sequence for $META. Wave 1-2 completed. Wave 1 of 3 completed and it's in Wave 2 of 3 correction. Wave 2 can retrace very deep. It has already retraced 61.8% of Wave 1. There is also a trendline support formed by connecting 2022 low with April 2025 low. It's also right at the 100 Week MA. My count is invalidated if NASDAQ:META drops below the beginning of Wave 1 at $480. My position I'm a long term investor of $META. I'm holding my shares. It's already a large position so I do not plan to add. I'm comfortable with just holding my position long term.
NASDAQ:METALong
by HeadsUp2021
S&P 500 — Double Top Setup by FRLThe market remains in an uptrend, but FRL highlights a critical moment. Price is testing the origin of the last impulse — the key FRL level that separates continuation from reversal. A confirmed close below this level will complete the double-top formation and shift the trend into a corrective phase. If confirmation comes, the natural FRL target lies at the 0.618 retracement, which aligns with the 200-day SMA — a strong confluence support. Previous similar FRL setup (fully played out): Nasdaq 100: Double Top or Double Bottom? (FRL Setup)
SPREADEX:SPXShort
by borschenkovitc
The 2025 structure currently matches ~85% of the 2022 pre-bear Mhistorically BTC often touches EMA89 then retests EMA55 before a bear market and right now the chart structure looks similar to past cycle tops Scenario A – Reclaim EMA55 (Bullish Recovery) Chance: ~35% Must close multiple weekly candles above EMA55 Would signal the bull trend is still intact Correction becomes similar to 2013/2017 mid-cycle crash Bullish targets: $110k $125k $135k final blow-off ============================= Scenario B – Rejection at EMA55 → Full Bear Market Chance: ~65% This is the historically normal outcome. If BTC: fails to reclaim the EMA55, AND closes weekly candles below EMA89 → Then this confirms a macro trend reversal. Bearish targets (based on past cycles): First major support: $72k–76k Cycle bottom zone: $55k–63k Extreme wick target (like 2020 crash): $48k (low probability)
COINBASE:BTCUSDLong
by YRashed
$ZEC 5-Wave Impulsive End of MoveZcash is one of those things that has thrown me off the most these past couple months. Everything else including CRYPTOCAP:BTC has been nuking, but CRYPTOCAP:ZEC has shown insane strength. It now appears this dino-coin is nearing the end of its run. 🚩 Double Top formed after impulsive 5-wave move. 🚩 Doji Candle followed by Bearish Engulfing on the Daily 🚩 Exaggerated Bearish Divergence on the RSI 🚩 Euphoria has been diminishing from the TL ⚠️ If it loses the 9EMA, this should confirm the next corrective wave down. I like the ideology behind Zcash and what it offers to the market, but it has no right to be pumping with ₿itcoin nuking.
CRYPTO:ZECUSDShort
by jonnieking
3
Newmont’s Uptrend May Be IntactNewmont has steadily rallied in 2025, and some traders may think its uptrend remains intact into yearend. The first pattern on today’s chart is the rebound from last month’s pullback. The gold miner is trying to hold a 50 percent retracement of the move, which may confirm its direction is still pointing higher. Second, NEM is back above its rising 50-day simple moving average. That may suggest its intermediate-term trend is still bullish. Third, the 8-day exponential moving average (EMA) is above the 21-day EMA. MACD is also rising. Those patterns may be consistent with a bullish short-term trend. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:NEM
by TradeStation
Aifinyo AG Increases Bitcoin Holdings with New Strategic PurchasAifinyo AG increases its digital asset presence as it buys an additional 2 Bitcoin. The company now holds 30.9 BTC. This fresh purchase reflects rising confidence and a clear commitment to its long-term blockchain vision. The Aifinyo Bitcoin strategy continues to expand as global interest in crypto grows. The company aims to stay ahead as more firms explore digital assets. The German publicly traded firm manages a growing financial technology platform. It helps businesses streamline growth and operational processes. Its decision to deepen its Bitcoin position highlights how traditional companies view crypto. The Aifinyo Bitcoin approach sends a signal about strong conviction and a belief in long-term digital value. Investors watch these moves closely as the market prepares for new cycles. Aifinyo AG understands how strategic adoption shapes financial positioning. Digital assets now influence treasury decisions across industries. The Aifinyo Bitcoin plan shows a shift toward future-focused financial models. More European companies explore similar strategies. The trend grows as Bitcoin gains attention as a treasury asset and a long-term store of value. Aifinyo AG Strengthens Its Corporate Vision Through Steady Accumulation Aifinyo AG builds its reputation as a forward-focused fintech company. The firm increases its crypto holdings in a consistent pattern. This latest addition strengthens its corporate crypto strategy. The company chooses long-term Bitcoin exposure rather than short-term speculation. This approach positions the firm for future growth as adoption expands. The move aligns with an ongoing industry pattern. Public companies add Bitcoin to diversify and protect treasuries. Aifinyo AG plans for resilient financial positioning. Its leadership sees Bitcoin as a strategic asset. The corporate crypto strategy allows the company to move with global technological change. Why Bitcoin Remains a Key Asset for Aifinyo and Other European Firms Bitcoin becomes more relevant in Europe as financial innovation grows. Companies look for alternative assets that store value. The Aifinyo Bitcoin buildup reflects this growing trend. The firm understands how limited supply and global demand create long-term benefits. This belief motivates regular and steady purchases. European fintech companies embrace digital transformation. They test new models that integrate blockchain technology. Bitcoin plays a strong role in treasury planning now. The Bitcoin treasury growth trend expands across several industries. Companies join the wave to strengthen balance sheets and diversify reserves. Regulators across Europe also explore new frameworks. These frameworks support responsible digital asset use. Aifinyo AG works within these evolving guidelines. The firm increases its holdings with clarity and strategic timing. The Bitcoin treasury growth movement gains traction as more firms follow similar steps. Conclusion Aifinyo AG joins a rising wave of European companies that embrace Bitcoin. The firm increases its holdings as part of a clear strategy. This approach highlights belief in digital finance. The corporate crypto strategy builds a strong foundation for the future. The company shows steady growth through calculated decisions. The move strengthens Aifinyo AG’s role in the fintech ecosystem. It aims for innovation and long-term economic resilience. The Bitcoin treasury growth trend continues shaping financial planning. Aifinyo AG stands among early movers that understand global digital adoption. This sets the stage for stronger performance as blockchain innovation expands.
INDEX:BTCUSDShort
by HCN-News12
$ETH accumulating around $3K?CRYPTOCAP:ETH accumulating around $3K? Spot on it’s coiling at ~$3,100 (up 3.44% short-term, per latest feeds), building steam after the recent dip. Next resistance retest at $3,400 makes sense: that’s the broken support-turned-resistance from early Nov, aligning with the 50-day MA and Fib 0.5 extension. Break it, and we’re eyeing $3,850–$3,900 by month-end (Fusaka upgrade hype + ETF inflows fueling the push). Whale zones at $2,800–$2,400? Bullish af—matches on-chain data where big players scooped $1.37B during the $3,331 breakdown (June highs echoed in Nov buys like Tom Lee’s $63.6M stack today). Wintermute’s loading millions amid the dump, signaling reversal vibes (last time = massive pump). If $2,800 holds (key Fib 0.618 + demand zone), that’s your dip-buy floor before $4K+. Mildly bullish here (70/30 odds on upside) RSI resetting from oversold, HAR dipping but whales countering retail sells. Load on #SorooshX signals if it tests $2,800. Your play? 😎 #ETH #Crypto
by sorooshx
Breakout in progress GALT is starting a breakout after reporting good news at the AASLD liver conference for the #1 untapped market for big pharma, liver cirrhosis. There is prior industry precedent that a buyout could send the stock price into the triple digits. Why GALT’s Fibrosis Data Are Better Than Any Other MASH Company 1. They are showing fibrosis improvement in true compensated cirrhosis (F4) — the population where EVERY OTHER DRUG HAS FAILED. Almost all other “great” fibrosis results in MASH come from F2–F3 populations (Akero, 89bio, Madrigal). Fibrosis moves easily there. But in biopsy-confirmed F4 cirrhosis with portal hypertension, fibrosis essentially does not reverse in modern trials. This is why Gilead, Intercept, NGM, Novartis, Genfit, and Madrigal all failed in this population. GALT is the first to repeatedly show biomarker improvement AND fewer clinical events in compensated cirrhosis. No other company has done that. 2. The magnitude of fibrosis-biomarker improvement is unusually large and consistent across ALL major antifibrotic markers. At 18 months (NAVIGATE): • Pro-C3 reduction: >50% vs baseline This is the main “fibrogenesis” marker. Competitors usually get ~20–30% reduction in easier F2–F3 patients. • ELF score: clinically meaningful drop Again, competitors rarely get ELF improvement in cirrhosis. • FibroScan liver stiffness: improved Liver stiffness almost always worsens in F4 patients. Belapectin produced improvement. • YKL-40 / other collagen markers: improved Indicates reduced macrophage-driven scarring. What’s unique: Other companies may improve one marker (e.g., ALT, MRI-PDFF, or PRO-C3), but GALT shows simultaneous improvement across the entire fibrosis parameter set in cirrhosis. That has not been replicated by any other company. 3. Only GALT has shown a link between fibrosis biomarkers → portal pressure improvement → fewer cirrhosis complications. This is the reason the field is paying attention. HVPG (portal pressure) improvement Belapectin produced meaningful drops in HVPG — the FDA’s gold-standard surrogate for preventing variceal bleeding, ascites, transplant, and death. No other MASH drug has ever shown a consistent HVPG improvement in cirrhosis. Reduced clinical progression Belapectin-treated patients developed fewer new esophageal varices, which is the #1 warning sign of impending decompensation. This matches the HVPG signal. It matches the biomarkers. This “full chain” alignment is unmatched: Fibrosis biomarkers improve Portal pressure decreases Varices occur less often Disease stays compensated Other companies haven’t shown this chain — not even close. 4. The 36-month follow-up CONFIRMED the benefit keeps going — something almost no MASH drug has ever shown. At 36 months: • New varices incidence: 12.4% at 2 mg/kg vs 23.4% placebo The advantage persisted for 3 years. This is extremely rare in cirrhosis. • Biomarker improvements remained stable PRO-C3, ELF, liver stiffness all stayed improved. Durability is critical: Many drugs show an early signal that disappears later. Belapectin’s signal strengthens with time. No other MASH drug has shown a 36-month antifibrotic durability signal with matching clinical outcomes. 5. Mechanistically, belapectin is the only drug directly targeting activated macrophage–galectin-3 fibrosis architecture. Other drugs target: Fat reduction (Madrigal) Metabolic pathways (89bio, Akero) FGF signaling Lipid metabolism Inflammation Those help in F2/F3 — but not in F4. Belapectin targets the scaffolding of fibrotic architecture itself by inhibiting galectin-3 on activated macrophages. This mechanism explains why: • GALT works in cirrhosis but others fail. • Biomarker improvements line up across every fibrosis marker. • HVPG drops. • 36-month clinical progression slows down. It’s the right mechanism for the right stage of disease. 6. The field desperately needs a drug for compensated cirrhosis — and GALT is alone. Every other company is fighting over: F2/F3 Early fibrosis Resmetirom-like mechanisms MRI-PDFF reductions Triglycerides ALT normalization Body-weight changes But none of that matters in F4. Regulators, hepatologists, and payers want something that: Slows portal pressure rise Prevents varices Delays decompensation Reduces need for transplant Only belapectin has shown all of that together. THE SIMPLE ANSWER GALT’s fibrosis data are better than any other MASH company because they succeed exactly where every other program has failed: reversing fibrosis biology, lowering portal pressure, and slowing clinical progression in real compensated cirrhosis — with signals that persist out to 36 months and are consistent across all major biomarker categories. No other company in MASH has shown: deep PRO-C3 reduction ELF improvement liver stiffness improvement HVPG reduction fewer varices 36-month durability in true F4 cirrhosis with a fibrosis-architecture mechanism GALT is alone in that category.
NASDAQ:GALTLong
by LGALS3
USD/JPY Facing Intervention Risk?The USD/JPY pair is trading around 155.40 today as the dollar gains ground against the yen amid a shift in risk sentiment and fading expectations of a near‑term rate cut by the Federal Reserve. The yen recovered slightly but remains under pressure after the pair hit multi‑month highs near 155.90; Japanese officials are signaling concern over the weakness and rising volatility in the currency market. So while the Yen has room to weaken on the back of rate differentials and fiscal consternation in Japan, further the risk of Japanese FX intervention is increasing, which could act as a ceiling on upside for the pair. In the above chart, USD/JPY rates have finally breached the February 2025 swing high near 155, the culmination of a two-week effort to scale resistance. Momentum continues to point higher, with USD/JPY well-supported by its 20-day exponential moving average (EMA) on pullbacks. The 2025 high at 158.88 is now in focus; a drop below the 20-day EMA would suggest that the rally has run out of steam.
by tastyfx